Researchers discovered hybrid extracellular vesicles (hEVs) in osteoarthritis patients' joint fluid that contain dual markers from inflammatory macrophages and cartilage cells. These hEVs reduce mitochondrial membrane potential through ADP/ATP translocase 1 disruption, causing irreversible mitochondrial fragmentation and depleting key metabolites including acetyl-CoA and α-ketoglutarate. This metabolite depletion alters histone modifications, driving cellular senescence in cartilage stem cells. This finding fundamentally reframes osteoarthritis pathology beyond simple wear-and-tear or inflammation. The discovery suggests why conventional anti-inflammatory treatments often fail—these hybrid vesicles create lasting metabolic damage that persists even after initial inflammatory triggers resolve. The irreversible nature distinguishes this from typical inflammatory damage, explaining osteoarthritis progression despite treatment. Therapeutically, this opens promising avenues combining ADT1 inhibitors with targeted metabolite supplementation. However, translation from joint fluid analysis to systemic intervention remains challenging. The metabolite replacement strategy—supplementing acetyl-CoA and α-ketoglutarate—could potentially apply to other age-related conditions involving mitochondrial dysfunction. This represents a paradigm shift toward viewing osteoarthritis as a vesicle-mediated metabolic disease rather than purely mechanical joint degradation.